June 20, 2019 20:05 UTC ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today the promotion of Teri Heiland, Ph.D. to Chief Scientific Officer. ...
February 28, 2019 04:05 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that a poster will be presented by Immunomic scientists at the American Association for Cancer ...
February 06, 2019 05:00 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that the company has granted Japanese animal ...
ITI's Michael Connolly, Manager of Process Development, presents a poster titled, "Functional evaluation of isoforms present in pDNA vaccines" at Aldevron's corporate offices located in Fargo, North Dakota A detailed abstract ...
Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company presented at the 2018 BIO Investor Forum held in San Francisco, CA on October 17-18. William Hearl, Ph.D., Immunomic’s Founder ...
Immunomic Therapeutics, Inc. Founder and CEO Bill Hearl Joins Rich Bendis for BioTalk Click to hear the interview: Bill Hearl Q&A Dr. Bill Hearl is the Founder and Chief Executive Officer ...
Our very own Dr. Heiland has been featured on BioBuzz. Click below to read the full Q&A Interview, as Dr. Heiland discusses our technology platform name change to UNITE and ...
Please read the article authored by ITI titled, “The Use and Misuse of Cancer Life Expectancy Statistics” which explores how GBM patients adjust and deal with dire life expectancy statistics. ...
May is Brain Tumor Awareness Month. In the United States, an estimated 700,000 people are living with a primary brain tumor and 79,000 more will be diagnosed this year. Gliomas ...
Congratulations to Immunomic and Astellas for winning the Best Therapeutic Vaccine award for ASP0892 (Peanut Vaccine)!
How Astellas is Working to Change Allergy Prevention through Partnership with Immunomic Therapeutics
Read how Astellas is working to address a high unmet medical need with first-of-its-kind allergy vaccine development through an innovative partnership. The following article was authored by Astellas and published on ...
December 13, 2017 07:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, is pleased to welcome Drew Pardoll, MD, Ph.D., Director of ...